The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations
Open accessAbstract
AIM: We assessed the dosage strengths of paliperidone palmitate 1-month (PP1M) long-acting injectable resulting in similar steady-state (SS) exposures to the dosage strengths of oral risperidone using pharmacokinetic (PK) simulations. METHODS: Population PK simulations of SS PK were performed using the PK models of oral risperidone and PP1M. The concentrations of active moiety (risperidone + paliperidone) from risperidone were compared to paliperidone concentrations resulting from PP1M administration. Similarity was assessed via graphical evaluation of median and 90% prediction intervals of SS PK profiles over 28 days. RESULTS: Oral risperidone doses of 1, 2, 3, 4, and 6 mg/d are expected to result in similar SS PK as PP1M doses of 25, 50, 75, 100, and 150 mg eq. (which correspond to 39, 78, 117, 156, and 234 mg of paliperidone palmitate) respectively (ie 25-fold dose conversion factor from oral risperidone to PP1M). CONCLUSIONS: This study provides clinicians with a practical guidance to establish suitable maintenance dose levels of PP1M and oral risperidone when transitioning patients from one formulation to another.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Paliperidone palmitate is the long-acting esterified formulation of paliperidone that is available in formulations for administration once monthly (PP1M) and once every 3 months (PP3M).
“Paliperidone palmitate is the long-acting esterified formulation of paliperidone that is available in formulations for administration once monthly (PP1M) and once every 3 months (PP3M) [74, 75].”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [74]
The Introduction identifies paliperidone palmitate as a long-acting injectable formulation available in 1-month (PP1M) and 3-month (PP3M) formulations. Our copy does not explicitly describe it as esterified, so that chemical detail is not verified by this source. (LLM, conf=0.82)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical pharmacology of atypical antipsychotics: an update
Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., & Altamura, A. C. (2014) · Technische Universität Dortmund · doi:10.17877/de290r-7037 · Cited by 250
Samtani, M. N., Vermeulen, A., & Stuyckens, K. (2009) · Clinical Pharmacokinetics · doi:10.2165/11316870-000000000-00000 · Cited by 170
Zhornitsky, S., & Stip, É. (2012) · Schizophrenia Research and Treatment · doi:10.1155/2012/407171 · Cited by 105
Gopal, S., Gassmann-Mayer, C., Palumbo, J., Samtani, M. N., Shiwach, R., & Alphs, L. D. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903482772 · Cited by 73
Self-citationDosing and Switching Strategies for Paliperidone Palmitate
Samtani, M. N., Gopal, S., Gassmann-Mayer, C., Alphs, L. D., & Palumbo, J. (2011) · CNS Drugs · doi:10.2165/11591690-000000000-00000 · Cited by 68
Self-citationVermeulen, A., Piotrovsky, V., & Ludwig, E. A. (2006) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-006-9040-2 · Cited by 57
Zhao, Y. J., Lin, L., Teng, M., Khoo, A. L., Soh, L. B., Furukawa, T. A., Baldessarini, R. J., Lim, B. P., & Sim, K. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.115.002576 · Cited by 51
Thyssen, A., Vermeulen, A., Fuseau, E., et al. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531730-000000000-00000 · Cited by 38
Gopal, S., Vermeulen, A., Nandy, P., et al. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1085849 · Cited by 31
Self-citationMagnusson, M. O., Samtani, M. N., Plan, E. L., Jonsson, E. N., Rossenu, S., Vermeulen, A., & Russu, A. (2017) · CNS Drugs · doi:10.1007/s40263-017-0416-1 · Cited by 25
Self-citationPeuskens, J., Rubio, G., & Schreiner, A. (2014) · Annals of General Psychiatry · doi:10.1186/1744-859x-13-10 · Cited by 14
Flagged first, then by citations
Cited by
Sorted by citations
Correll, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205
Self-citation
Metadata
- Authors
- Russu, A., Kern Sliwa, J., Ravenstijn, P., Singh, A., Mathews, M., Kim, E., & Gopal, S.
- Affiliations
- Janssen (Belgium) (BE)
- Janssen Scientific Affairs, LLC; Titusville NJ USA
- Janssen Research & Development; Titusville NJ USA
- Janssen Scientific Affairs (United States) (US)
- Corresponding author
- Russu, Alberto
- Venue
- International Journal of Clinical Practice
- Publisher
- Wiley
- Published
- 2018-04-30
- Volume
- 72
- Issue
- 6
- Pages
- e13089
- ISSN
- 1368-5031 (ISSN-L)
- PMC
- PMC6175146
- OpenAlex
- W2801802344
- Cited by
- 19
- References
- 11
- Citations by year
- 2025: 5 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 1 · 2019: 1 · 2018: 1
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- International Journal of Clinical Practice (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- paliperidone palmitate, risperidone, long-acting injectable antipsychotics, dose conversion, maintenance dose, steady-state pharmacokinetics, pharmacokinetic simulation, dose equivalence
- MeSH terms
- Paliperidone Palmitate, Administration, Oral, Delayed-Action Preparations, Humans, Schizophrenia, Antipsychotic Agents, Practice Guidelines as Topic, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
